4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. - PE Ratioverified

FDMT

Price:

$9.66

Market Cap:

$504.99M

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond t...[Read more]

Industry

Biotechnology

IPO Date

2020-12-11

Stock Exchange

NASDAQ

Ticker

FDMT

The PE Ratio as of June 2026 (TTM) for 4D Molecular Therapeutics, Inc. (FDMT) is -3.74

According to 4D Molecular Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.74. This represents a change of -13358.68% compared to the average of 0.03 of the last 4 quarters.

4D Molecular Therapeutics, Inc. (FDMT) Historical PE Ratio (quarterly & annually)

How has FDMT PE Ratio performed in the past?

The mean historical PE Ratio of 4D Molecular Therapeutics, Inc. over the last ten years is -19.47. The current -3.74 PE Ratio has changed 1.82% with respect to the historical average. Over the past ten years (40 quarters), FDMT's PE Ratio was at its highest in in the December 2025 quarter at 5.51. The PE Ratio was at its lowest in in the September 2020 quarter at -28.13.

Quarterly (TTM)
Annual

Average

-19.47

Median

-8.92

Minimum

-53.29

Maximum

-1.87

4D Molecular Therapeutics, Inc. (FDMT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of 4D Molecular Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 65.81%

Maximum Annual PE Ratio = -1.87

Minimum Annual Increase = -76.20%

Minimum Annual PE Ratio = -53.29

Quarterly (TTM)
Annual
YearPE RatioChange
2025-3.1065.81%
2024-1.87-76.20%
2023-7.8510.31%
2022-7.12-20.18%
2021-8.92-54.38%
2020-19.55-3.45%
2019-20.25-62.00%
2018-53.290%

4D Molecular Therapeutics, Inc. (FDMT) Average PE Ratio

How has FDMT PE Ratio performed in the past?

The current PE Ratio of 4D Molecular Therapeutics, Inc. (FDMT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-4.27

5-year avg

-5.77

10-year avg

-19.47

4D Molecular Therapeutics, Inc. (FDMT) PE Ratio vs. Peers

How is FDMT’s PE Ratio compared to its peers?

4D Molecular Therapeutics, Inc.’s PE Ratio is greater than KalVista Pharmaceuticals, Inc. (-8.36), less than Omeros Corporation (7.91), less than Bicycle Therapeutics plc (-1.27), less than Gossamer Bio, Inc. (-0.21), greater than Lexicon Pharmaceuticals, Inc. (-28.15), less than ADC Therapeutics S.A. (-1.04), less than Neumora Therapeutics, Inc. Common Stock (-1.14), less than REGENXBIO Inc. (-1.39), less than Prothena Corporation plc (-3.18), greater than Compass Therapeutics, Inc. (-5.52),

Build a custom stock screener for 4D Molecular Therapeutics, Inc. (FDMT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 4D Molecular Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

4D Molecular Therapeutics, Inc. (FDMT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like 4D Molecular Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is 4D Molecular Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for 4D Molecular Therapeutics, Inc. (FDMT)?

What is the highest PE Ratio for 4D Molecular Therapeutics, Inc. (FDMT)?

What is the 3-year average PE Ratio for 4D Molecular Therapeutics, Inc. (FDMT)?

What is the 5-year average PE Ratio for 4D Molecular Therapeutics, Inc. (FDMT)?

How does the current PE Ratio for 4D Molecular Therapeutics, Inc. (FDMT) compare to its historical average?